Globus Medical boosts margins and cash flow with flexible leasing and post-acquisition growth.

Globus Medical is expanding its installed base through flexible leasing models, focusing on recurring high-margin implant sales rather than upfront capital revenue. Following its integration with NuVasive, the company has seen adjusted EBITDA margins rise to 35.4% and nearly doubled its free cash flow year-over-year. Despite a decline in segment revenue, placements of its ExcelsiusGPS system grew by 25%, supporting a shift toward a more recurring and cash-generative business model. Trading at a discount to sector EV/EBITDA multiples, Globus Medical's growth, margin expansion, and strong market position in the spine sector underpin a positive long-term outlook.

Globus Medical's shift toward recurring revenue and margin expansion aligns with its current market performance. On Pluang, GMED trades at USD 79.99, up 2.47% as of Nov 03, 2026 01:11 WIB, reflecting investor interest in its evolving business model. The stock's market cap stands at $10.48 billion, with a 52-week range between $60.39 and $96.82, indicating room for growth within the health sector.